COYA - Coya Therapeutics, Inc.
收市後：
| 前收市價 | 4.5700 |
| 開市 | 4.4700 |
| 買盤 | 0.0000 x 900 |
| 賣出價 | 0.0000 x 1300 |
| 今日波幅 | 4.0900 - 4.7000 |
| 52 週波幅 | 3.6850 - 8.0000 |
| 成交量 | |
| 平均成交量 | 116,796 |
| 市值 | 41.781M |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.3700 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 17.33 |
BenzingaWhy Coya Therapeutics Shares Are Shooting Higher Today
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer's disease. Treatment with COYA 301 resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE), compared to the mean MMSE score at baseline (p=0.015). Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the
BenzingaCoya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients
Coya Therapeutics Inc (NASDAQ: COYA) reported 48-week clinical data for its proof-of-concept open-label study in 4 Amyotrophic Lateral Sclerosis (ALS) patients indicating that treatment with COYA 302 appeared to ameliorate disease progression. During the 48-week treatment period, COYA 302 appeared to be well tolerated. Preliminary efficacy of COYA 302 was measured by the ALSFRS-R scale, a validated rating tool for monitoring the progression of disability in ALS patients. The mean (±SD) ALSFRS-R